Holen Sie sich die Stockscreener-App
14.89
3.70%
0.565
Schlusskurs vom Vortag:
$14.32
Offen:
$14.62
24-Stunden-Volumen:
52,690
Relative Volume:
0.90
Marktkapitalisierung:
$104.33M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.578
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+6.26%
1M Leistung:
+22.57%
6M Leistung:
+168.63%
1J Leistung:
+84.99%
1-Tages-Spanne:
$14.30
$15.35
1-Wochen-Bereich:
$13.89
$16.72
52-Wochen-Spanne:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
14.86 | 100.60M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
How Atara Biotherapeutics Inc. stock reacts to global recession fearsJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
How to use Fibonacci retracement on Atara Biotherapeutics Inc.Buy Signal & Fast Gain Swing Alerts - newser.com
Will Atara Biotherapeutics Inc. stock maintain growth storyMarket Risk Analysis & Consistent Return Strategy Ideas - newser.com
Volume spikes in Atara Biotherapeutics Inc. stock – what they meanMarket Sentiment Review & Weekly Hot Stock Watchlists - newser.com
Can you recover from losses in Atara Biotherapeutics Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com
Chart based exit strategy for Atara Biotherapeutics Inc.Market Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Using economic indicators to assess Atara Biotherapeutics Inc. potentialJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Will Atara Biotherapeutics Inc. continue its uptrendWeekly Risk Summary & Precise Buy Zone Tips - newser.com
What hedge fund activity signals for Atara Biotherapeutics Inc. stockJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
How rising interest rates impact Atara Biotherapeutics Inc. stockRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Atara Biotherapeutics' (ATRA) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry - simplywall.st
Atara Biotherapeutics Inc. stock trendline breakdownQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Statistical indicators supporting Atara Biotherapeutics Inc.’s strengthJuly 2025 Rallies & Verified Momentum Stock Ideas - newser.com
Pattern recognition hints at Atara Biotherapeutics Inc. upside2025 Momentum Check & Reliable Entry Point Trade Alerts - newser.com
Atara Biotherapeutics Inc Stock Analysis and ForecastAutomated Trading Signals & Your Free Entry to Smart Investing Starts Here - earlytimes.in
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Price Target from Brokerages - Defense World
How Atara Biotherapeutics Inc. (AT20) stock stacks up against competitorsNew Guidance & Real-Time Market Trend Scan - newser.com
Is Atara Biotherapeutics Inc. stock positioned for long term growthPortfolio Value Report & Expert Verified Stock Movement Alerts - newser.com
What drives Atara Biotherapeutics Inc stock priceStock Price Divergence & Low Entry Capital Stocks - earlytimes.in
Can swing trading help recover from Atara Biotherapeutics Inc. losses2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Yahoo Finance
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
Analyzing net buyer seller activity in Atara Biotherapeutics Inc.Quarterly Investment Review & Reliable Volume Spike Alerts - newser.com
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - inkl
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Aug 18 '25 |
Sale |
11.61 |
1,809 |
21,009 |
35,258 |
| Panacea Innovation Ltd | 10% Owner |
Aug 15 '25 |
Buy |
12.19 |
55,000 |
670,422 |
1,405,000 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):